Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells

REFERENCES

• Wu AH, Fontham ET, Reynolds P, Greenberg RS, Buffler P, Liff J, Boyd P, Henderson BE, Correa P: Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol. 1995;141:1023–1032.
   PubMed Web of Science ®Google Scholar
• Cohen BH, Diamond EL, Graves CG, Kreiss P, Levy DA, Menkes HA, Permutt S, Quaskey S, Tockman MS: A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet. 1977;2:523–526.
   PubMed Web of Science ®Google Scholar
• Duperron C, Castonguay A: Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis. 1997;18:1001–1006.
   PubMed Web of Science ®Google Scholar
• Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA, Geraci MW: Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res. 2002;62:734–740.
   PubMed Web of Science ®Google Scholar
• Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP, Geraci MW: Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res. 2004;64:5897–5904.
   PubMed Web of Science ®Google Scholar
• Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Barthel B, Meyer AM, Thompson DC, Malkinson AM: Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res. 2002;62:6850–6856.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249.
   PubMed Web of Science ®Google Scholar
• Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga M, Ando M: Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res. 1997;88:1190–1198.
   PubMedGoogle Scholar
• Liu CY, Wang CH, Chen TC, Lin HC, Yu CT, Kuo HP: Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer. 1998;78:534–541.
   PubMed Web of Science ®Google Scholar
• Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, Agarwal R: Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst. 2006;98:846–855.
   PubMed Web of Science ®Google Scholar
• Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, Radcliffe RA, Malkinson AM, Agarwal R: Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res. 2009;2:74–83.
   PubMed Web of Science ®Google Scholar
• Castelao JE, Bart RD, III, DiPerna CA, Sievers EM, Bremner RM: Lung cancer and cyclooxygenase-2. Ann Thorac Surg. 2003;76:1327–1335.
   PubMed Web of Science ®Google Scholar
• Bauer AK, Dwyer-Nield LD, Malkinson AM: High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis. 2000;21:543–550.
   PubMed Web of Science ®Google Scholar
• Muscat JE, Chen SQ, Richie JP, Jr., Altorki NK, Citron M, Olson S, Neugut AI, Stellman SD: Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer. 2003;97:1732–1736.
   PubMed Web of Science ®Google Scholar
• Moody TW, Leyton J, Zakowicz H, Hida T, Kang Y, Jakowlew S, You L, Ozbun L, Zia H, Youngberg J, Malkinson A: Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res. 2001;21:1749–1755.
   PubMed Web of Science ®Google Scholar
• Rioux N, Castonguay A: Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 1998;58:5354–5360.
   PubMed Web of Science ®Google Scholar
• Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, Johnson DH, Morrow JD: Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 2004;334:266–275.
   PubMed Web of Science ®Google Scholar
• Nana-Sinkam P, Golpon H, Keith RL, Oyer RJ, Sotto-Santiago S, Moore MD, Franklin W, Nemenoff RA, Geraci MW: Prostacyclin in human non-small cell lung cancers. Chest. 2004;125:141S.
   PubMed Web of Science ®Google Scholar
• Dwyer-Nield LD, Srebernak MC, Barrett BS, Ahn J, Cosper P, Meyer AM, Kisley LR, Bauer AK, Thompson DC, Malkinson AM: Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic vs. non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis. 2005;26:1196–1206.
   PubMed Web of Science ®Google Scholar
• Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW: Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 2005;167:1763–1775.
   PubMed Web of Science ®Google Scholar
• Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL: Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator–activated receptor gamma. Cancer Prev Res (Phila Pa). 2008;1:349–356.
   PubMed Web of Science ®Google Scholar
• Gupta RA, Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11–21.
   PubMed Web of Science ®Google Scholar
• Belvisi MG, Saunders MA, Haddad EL, Hirst SJ, Yacoub MH, Barnes PJ, Mitchell JA: Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type. Br J Pharmacol. 1997;120:910–916.
   PubMed Web of Science ®Google Scholar
• Barnes PJ: Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev. 2003;14:511–522.
   PubMed Web of Science ®Google Scholar
• Robbins RA, Springall DR, Warren JB, Kwon OJ, Buttery LD, Wilson AJ, Adcock IM, Riveros-Moreno V, Moncada S, Polak J: Inducible nitric oxide synthase is increased in murine lung epithelial cells by cytokine stimulation. Biochem Biophys Res Commun. 1994;198:835–843.
   PubMed Web of Science ®Google Scholar
• Thompson DC, Porter SE, Bauer AK, Das KC, Ou B, Dwyer-Nield L, White CW, Malkinson AM: Cytokine-induced nitric oxide formation in normal but not in neoplastic murine lung epithelial cell lines. Am J Physiol. 1998;274:L922– L932.
   PubMed Web of Science ®Google Scholar
• Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, Shepherd FA: Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res. 2003;9:2241–2247.
   PubMed Web of Science ®Google Scholar
• Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, Hirata K, Wanibuchi H, Fukushima S, Inoue K, Yoshikawa J: Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer. 2003;41:123–130.
   PubMed Web of Science ®Google Scholar
• Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, Quero C, Soria JC, Martin-Algarra S, Manzano RG, Montuenga LM: ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer. 2004;90:1047–1052.
   PubMed Web of Science ®Google Scholar
• Malkinson AM, Dwyer-Nield LD, Rice PL, Dinsdale D: Mouse lung epithelial cell lines—tools for the study of differentiation and the neoplastic phenotype. Toxicology. 1997;123:53–100.
   PubMed Web of Science ®Google Scholar
• Bentel JM, Lykke AW, Smith GJ: Cloned murine non-malignant, spontaneously transformed and chemical tumour-derived cell lines related to the type 2 pneumocyte. Cell Biol Int Rep. 1989;13:729–738.
   PubMedGoogle Scholar
• Pan YH, Nuzum EO, Hanson LA, Beer DG: Ki-ras activation and expression in transformed mouse lung cell lines. Mol Carcinog. 1990;3:279–286.
   PubMed Web of Science ®Google Scholar
• Brash AR, Jackson EK, Saggese CA, Lawson JA, Oates JA, FitzGerald GA: Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther. 1983;226:78–87.
   PubMed Web of Science ®Google Scholar
• Malkinson AM, Miley FB, Chichester CH, Plopper CG: Isolation of nonciliated bronchiolar (Clara) epithelial cells from mouse lung. Methods Toxicol. 1993;1A:123–133.
   Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265–275.
   PubMed Web of Science ®Google Scholar
• Krishan A: Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975;66:188–193.
   PubMed Web of Science ®Google Scholar
• Rice PL, Goldberg RJ, Ray EC, Driggers LJ, Ahnen DJ: Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res. 2001;61:1541–1547.
   PubMed Web of Science ®Google Scholar
• Dwyer-Nield LD, Dinsdale D, Cohen JJ, Squier MK, Malkinson AM: Morphological assessment of apoptosis in human lung cells. Methods Mol Med. 2003;74:283–297.
   PubMedGoogle Scholar
• Franklin CC, Srikanth S, Kraft AS: Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc Natl Acad Sci U S A. 1998;95:3014–3019.
   PubMed Web of Science ®Google Scholar
• Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95–105.
   PubMed Web of Science ®Google Scholar
• Mamay CL, Schauer IE, Rice PL, Dwyer-Nield LD, You M, Sclafani RA, Malkinson AM: Cyclin D1 as a proliferative marker regulating retinoblastoma phosphorylation in mouse lung epithelial cells. Cancer Lett. 2001;168:165–172.
   PubMed Web of Science ®Google Scholar
• Meuwissen R, Berns A: Mouse models for human lung cancer. Genes Dev. 2005;19:643–664.
   PubMed Web of Science ®Google Scholar
• Zerbe LK, Dwyer-Nield LD, Fritz JM, Redente EF, Shroyer RJ, Conklin E, Kane S, Tucker C, Eckhardt SG, Gustafson DL, Iwata KK, Malkinson AM: Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol. 2008;62:605–620.
   PubMed Web of Science ®Google Scholar
• Ballaz S, Mulshine JL: The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer. 2003;5:46–62.
   PubMedGoogle Scholar
• Yao B, Zhang Y, Delikat S, Mathias S, Basu S, Kolesnick R: Phosphorylation of Raf by ceramide-activated protein kinase. Nature. 1995;378:307–310.
   PubMed Web of Science ®Google Scholar
• Hildt E, Oess S: Identification of Grb2 as a novel binding partner of tumor necrosis factor (TNF) receptor I. J Exp Med. 1999;189:1707–1714.
   PubMed Web of Science ®Google Scholar
• Stancato LF, Yu CR, Petricoin EF III, Larner AC: Activation of Raf-1 by interferon gamma and oncostatin M requires expression of the Stat1 transcription factor. J Biol Chem. 1998;273:18701–18704.
   PubMed Web of Science ®Google Scholar
• Sakatsume M, Stancato LF, David M, Silvennoinen O, Saharinen P, Pierce J, Larner AC, Finbloom DS: Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent. J Biol Chem. 1998;273:3021–3026.
   PubMed Web of Science ®Google Scholar
• Loewen GM, Tracy E, Blanchard F, Tan D, Yu J, Raza S, Matsui S, Baumann H: Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines. BMC Cancer. 2005;5:145.
   PubMed Web of Science ®Google Scholar
• Asano K, Nakamura H, Lilly CM, Klagsbrun M, Drazen JM: Interferon gamma induces prostaglandin G/H synthase-2 through an autocrine loop via the epidermal growth factor receptor in human bronchial epithelial cells. J Clin Invest. 1997;99:1057–1063.
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Song K, Marshall T, Brock T: Translocation of cytosolic phospholipase A2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis. Biochem J. 1996;318(Pt 3):797–803.
   PubMedGoogle Scholar
• Xie W, Herschman HR: Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J Biol Chem. 1996;271:31742–31748.
   PubMed Web of Science ®Google Scholar
• Kristof AS, Marks-Konczalik J, Moss J: Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation. J Biol Chem. 2001;276:8445–8452.
   PubMed Web of Science ®Google Scholar
• Hausel P, Latado H, Courjault-Gautier F, Felley-Bosco E: Src-mediated phosphorylation regulates subcellular distribution and activity of human inducible nitric oxide synthase. Oncogene. 2006;25:198–206.
   PubMed Web of Science ®Google Scholar
• Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA: Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol. 2001;167:6533– 6544.
   PubMed Web of Science ®Google Scholar
• Weinstein IB: Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science. 2002;297:63–64.
   PubMed Web of Science ®Google Scholar
• Hu Y, Bally M, Dragowska WH, Mayer L: Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther. 2003;2:641–649.
   PubMed Web of Science ®Google Scholar
• Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA: Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 2005;65:8423–8432.
   PubMed Web of Science ®Google Scholar
• Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway [review]. Int J Oncol. 2003;22:469–480.
   PubMed Web of Science ®Google Scholar
• Lu G, Liao J, Yang G, Reuhl KR, Hao X, Yang CS: Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res. 2006;66:11494–11501.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weissleder R, Mahmood U, Cantley LC, Wong KK: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14:1351–1356.
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS: Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res. 2008;14:3651– 3656.
   PubMed Web of Science ®Google Scholar